Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Erin A Bohula May, M.D., D.Phil.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017 Feb 28; 69(8):911-921. PMID: 28231942.
    View in: PubMed
  2. Eisen A, Bonaca MP, Jarolim P, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clin Chem. 2017 Jan; 63(1):307-315. PMID: 28062625.
    View in: PubMed
  3. Bohula EA, Antman EM. Management of Non-ST-Elevation Myocardial Infarction: The Bright Gleam of Progress, but Much Work Remains. JAMA. 2016 Sep 13; 316(10):1045-7. PMID: 27574716.
    View in: PubMed
  4. Eisen A, Cannon CP, Blazing MA, Bohula EA, Park JG, Murphy SA, White JA, Giugliano RP, Braunwald E. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016 12 21; 37(48):3576-3584. PMID: 27569841.
    View in: PubMed
  5. Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation. 2016 Jul 26; 134(4):304-13. PMID: 27440003.
    View in: PubMed
  6. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016 Jul 05; 134(1):24-36. PMID: 27358434.
    View in: PubMed
  7. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White J, Tershakovec AM, Blazing MA, Braunwald E. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation. 2016 Mar 29; 133(13):e463. PMID: 27022050.
    View in: PubMed
  8. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016 Feb 02; 67(4):353-361. PMID: 26821621.
    View in: PubMed
  9. Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. Circulation. 2015 Nov 17; 132(20):1871-9. PMID: 26338971.
    View in: PubMed
  10. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015 Sep 29; 132(13):1224-33. PMID: 26330412.
    View in: PubMed
  11. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18; 372(25):2387-97. PMID: 26039521.
    View in: PubMed
  12. Berg DD, Sukul D, O'Brien M, Scirica BM, Sobieszczyk PS, Olenchock BA, Bohula EA, Morrow DA. Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2016 Apr; 5(2):108-16. PMID: 25931573; PMCID: PMC4627853 [Available on 04/01/17].
  13. Bohula May EA, Bonaca MP, Jarolim P, Antman EM, Braunwald E, Giugliano RP, Newby LK, Sabatine MS, Morrow DA. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014 Jan; 60(1):158-64. PMID: 24052087.
    View in: PubMed
  14. Bohula May EA, Faxon D. Transcatheter aortic valve replacement: history and current status. Trends Cardiovasc Med. 2013 Jul; 23(5):172-8. PMID: 23375629.
    View in: PubMed
  15. Yeh AH, Bohula EA, Macaulay VM. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene. 2006 Oct 26; 25(50):6574-81. PMID: 16715137.
    View in: PubMed
  16. Bohula EA, Playford MP, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs. 2003 Oct; 14(9):669-82. PMID: 14551500.
    View in: PubMed
  17. Barelle CJ, Bohula EA, Kron SJ, Wessels D, Soll DR, Schäfer A, Brown AJ, Gow NA. Asynchronous cell cycle and asymmetric vacuolar inheritance in true hyphae of Candida albicans. Eukaryot Cell. 2003 Jun; 2(3):398-410. PMID: 12796285; PMCID: PMC161449.
  18. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM, Macaulay VM. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem. 2003 May 02; 278(18):15991-7. PMID: 12604614.
    View in: PubMed
  19. Macaulay VM, Salisbury AJ, Bohula EA, Playford MP, Smorodinsky NI, Shiloh Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene. 2001 Jul 05; 20(30):4029-40. PMID: 11494131.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bohula May's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (138)
Explore
_
Co-Authors (14)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.